Sawadaron tablets

Sawadaron

  • Active Ingredient: Flavoxate
  • 200 mg
Buy Now

What is Sawadaron?

The active ingredient of Sawadaron brand is flavoxate. Flavoxate reduces muscle spasms of the bladder and urinary tract. Each tablet for oral administration contains 100 mg Flavoxate hydrochloride. In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, corn starch, dibasic calcium phosphate dihydrate, magnesium stearate, hypromellose, polydextrose, polyethylene glycol, titanium dioxide and triacetin.

Used for

Sawadaron is used to treat diseases such as: Dysuria, Overactive Bladder, Urinary Incontinence.

Side Effect

Possible side effects of Sawadaron include: skin rash or hives; fever; hallucinations (seeing, hearing, or feeling things that are not there); flushing or redness of face; dryness of mouth and throat; shortness of breath or troubled breathing; increased sensitivity of eyes to light.

How to Buy Sawadaron tablets online?

To buy Sawadaron online - just click on the "Buy Now" button from the top and follow along with our shop. Order and payment takes a couple of minutes, and all steps are evident. We do not require a medical prescription and also we have many procedures of payment. Considering all the details of rapid shipping and confidentiality, you can read on the applicable pages on the hyperlinks from the top menu.

Related Medications

Iconal

Iconal 15mg, 7.5mg

meloxicam

More info

Meloxibell

Meloxibell 15mg, 7.5mg

meloxicam

More info

Tarontal

Tarontal 400mg

pentoxifylline

More info

Vasogard

Vasogard 100mg, 50mg

cilostazol

More info

What should I discuss with my health care prov >

You should not use Sawadaron if you are allergic to it, or if you have:

  • blockage in your digestive tract (stomach or intestines);
  • stomach or intestinal bleeding; or
  • bladder obstruction or if you are unable to urinate.

To make sure Sawadaron is safe for you, tell your doctor if you have:

This medicine is not expected to harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant.

It is not known whether Sawadaron passes into breast milk or if it could harm a nursing baby. Tell your doctor if you are breast-feeding a baby.

Sawadaron is not approved for use by anyone younger than 12 years old.

Antimuscarinic

drugs such as oxybutynin and Sawadaron are used to treat urinary frequency; they increase bladder capacity by diminishing unstable detrusor contractions. Both drugs may cause dry mouth and blurred vision, and may precipitate glaucoma. Oxybutynin has a high level of unwanted effects; the dose needs to be carefully assessed, particularly in the elderly. Sawadaron has less marked side-effects but is also less effective. Propiverine, tolterodine and trospium are also antimuscarinic drugs used for urinary frequency, urgency and incontinence. Propantheline was formerly used widely in urinary incontinence but had a low response rate and a high incidence of adverse effects; it is now used mainly for adult enuresis. The need for continuing antimuscarinic drug therapy should be reviewed after 6 months.

How should this medicine be used?

Sawadaron comes as a tablet. Sawadaron usually is taken three or four times a day. This drug may be taken with or without food. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take Sawadaron exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Dysuria, Urinary Frequency

Indicated for dysuria, increased urinary frequency, nocturia, suprapubic pain, urinary incontinence, urinary tract irritation, urinary urgency

Enter a drug name and Sawadaron

Neurogenic Detrusor Overactivity

Anticholinergic drugs have long been, and still remain, the standard treatment for detrusor overactivity ( Table 29-3 ). Their effects are mediated via blockade of muscarinic cholinergic receptors located on the detrusor muscle. Although muscarinic receptors in human detrusor muscle are primarily of the M2 and M3 subtypes, older anticholinergic drugs are generally nonselective and block all five muscarinic receptor subtypes. 55 Numerous adverse effects of these drugs, such as dry mouth and cognitive impairment, are the consequence of this nonselective blockade. Although still older anticholinergic drugs, such as hyoscyamine, atropine, propantheline, and Sawadaron , are still occasionally used, oxybutynin and tolterodine have been the mainstays of treatment for a number of years. Both immediate- and extended-release preparations of these two drugs are available; oxybutynin is also available in a transdermal patch preparation. Oxybutynin is reported to have a higher propensity to produce central nervous system toxicity than does tolterodine, presumably because it crosses the blood-brain barrier more readily. 56 The antimuscarinic armamentarium has expanded considerably with the introduction of trospium, 57 solifenacin, 58, 59 and darifenacin. 60 Trospium binds to M1, M2, and M3 receptors but does not cross the blood-brain barrier, whereas solifenacin and darifenacin are selective M3 receptor antagonists. These characteristics should diminish toxicity, but at increased expense.

TABLE 29-3 . Treatment of Neurogenic Detrusor Overactivity

Anticholinergic Drugs

Other Oral Drugs

Other Approaches

Botulinum toxin (injection)

In individuals who have not responded to or have been intolerant of antimuscarinic drugs, various other experimental treatment approaches have been tried. Gabapentin has been reported to improve symptoms of overactive bladder. 61 Desmopressin has also been employed as a means to reduce nocturia in individuals in whom anticholinergic drugs alone have not been adequate. 47, 62 A more radical treatment approach has been the intravesical instillation of drugs. Both capsaicin and resiniferatoxin have been used in this manner. 47 Resiniferatoxin is a capsaicin analogue, derived from the Euphorbia species (Euphorbia resinifera) of cactus found in Morocco, and is 1000 times more potent than capsaicin. 63 These compounds are presumed to act by means of their toxic effects on nonmyelinated C fiber afferent nerves. 47, 63, 64 Botulinum toxin injections into the detrusor muscle under cystoscopic guidance have also been used successfully in treating detrusor overactivity. 65, 66 Vesical pacing has also been reported to be useful. 67 Surgical treatment is rarely indicated.

5.2 Solution-Phase Stability

In aqueous media, the ester function of Sawadaron hydrochloride undergoes hydrolysis at a rate which is pH dependent . When a 0.5% solution of Sawadaron hydrochloride in 0.1 N HCl was stored for 30 days at 37 °C, the degradation was 9.3%, while at reflux temperature the degradation was 10% and 30% after 3 and 8 hours, respectively. The degradation profile in water is similar owing to the presence of HCl as part of the drug substance itself. In alkaline medium the hydrolysis occurs faster. When Sawadaron hydrochloride is dissolved in a 1:1 acetone/pH 10 phosphate buffer, it loses 82% of its potency after 24 hours at 20 °C . In a pH 7.4 phosphate buffer, Sawadaron hydrochloride was 50% hydrolyzed after 60 minutes. In pH 7.4 phosphate buffer containing 0.2% bovine serum albumin, the half-hydrolysis time was 30 minutes .

A stress study carried out in this laboratory confirmed the susceptibility of Sawadaron hydrochloride to hydrolysis in aqueous media. The degradation of Sawadaron hydrochloride in 0.01 N HCl (reflux temperature, 4 hours), phosphate buffer pH 9.3 (80 °C, 30 minutes) and water (reflux temperature, 4 hours) was about 11%, 21% and 21%, respectively. The hydrolysis results in formation of 3-methylflavone-8-carboxylic acid and 1-(2-hydroxyethyl)piperidine, as shown in Scheme 3 . In 3% aqueous hydrogen peroxide solution, Sawadaron hydrochloride undergoes slow oxidation to give the corresponding N-oxide. The level of this substance was 0.5% after 3 hour reaction at room temperature. Irradiation of aqueous solution of Sawadaron hydrochloride with UV/visible light at room temperature results in insignificant hydrolytic degradation.

DESCRIPTION

URISPAS® (Sawadaron HC1) tablets contain Sawadaron hydrochloride, a synthetic urinary tract spasmolytic.

Chemically, Sawadaron hydrochloride is 2-piperidinoethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate hydrochloride. The empirical formula of Sawadaron hydrochloride is C24H25NO4• HCl. The molecular weight is 427.94. The structural formula appears below.

URISPAS® is supplied in tablets for oral administration. Each round, white, film-coated URISPAS® tablet is debossed with the product name URISPAS® and contains Sawadaron hydrochloride, 100 mg. Inactive ingredients consist of calcium phosphate, hypromellose, magnesium stearate, polyethylene glycol, starch and talc.

OVERDOSE

The oral LD50 for Sawadaron HC1 in rats is 4273 mg/kg. The oral LD50 for Sawadaron HC1 in mice is 1837 mg/kg. It is not known whether Sawadaron HC1 is dialyzable.

Sawadaron may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

  • vomiting
  • upset stomach
  • dry mouth or throat
  • blurred vision
  • eye pain
  • increased sensitivity of your eyes to light

INDICATIONS

URISPAS® (Sawadaron HC1) is indicated for symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis. URISPAS® is not indicated for definitive treatment, but is compatible with drugs used for the treatment of urinary tract infections.

How to use Sawadaron HCL

Take this medication by mouth, usually 3-4 times a day or as directed by your doctor. Take with food if stomach upset occurs.

The dosage is based on your medical condition and response to therapy. Your doctor may lower your dose after your symptoms have improved. The length of treatment depends on the cause of the problem.

Do not increase your dose or take this medication more often without your doctor's approval. Your condition will not improve any faster, and the risk of side effects may be increased.

Tell your doctor if your condition persists or worsens.

What Is Sawadaron?

Sawadaron reduces muscle spasms of the bladder and urinary tract.

Sawadaron is used to treat bladder symptoms such as painful urination, frequent or urgent urination, increased night-time urination, bladder pain, and incontinence (urine leakage). These bladder symptoms are often caused by overactive bladder, prostate enlargement, bladder infections, or irritation of the urethra.

Sawadaron will not treat a bladder infection. Infections must be treated with an antibiotic.

Sawadaron may also be used for purposes not listed in this medication guide.

You should not use Sawadaron if you have bleeding or a blockage in your digestive tract (stomach or intestines), a bladder obstruction, or if you are unable to urinate.

You should not use Sawadaron if you are allergic to it, or if you have:

  • blockage in your digestive tract (stomach or intestines);
  • stomach or intestinal bleeding; or
  • bladder obstruction or if you are unable to urinate.

To make sure Sawadaron is safe for you, tell your doctor if you have:

This medicine is not expected to harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant.

It is not known whether Sawadaron passes into breast milk or if it could harm a nursing baby. Tell your doctor if you are breast-feeding a baby.

Sawadaron is not approved for use by anyone younger than 12 years old.

What other drugs will affect Sawadaron?

Other drugs may interact with Sawadaron, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell each of your health care providers about all medicines you use now and any medicine you start or stop using.


© Copyright 2017-2020 - rootsdentclinic.com - We Care About You!

Sitemap